This is the logo of the provider
EASD 2025 15 - 19 September 2025

Revolutionising Cardiometabolic Health: Innovating, Transforming and Progressing Care

Meeting description
Chair teaser video
04:10
Add to Calendar
Download agenda
Monday, 15 September 2025
09:00 - 10:40
(CEST)

Part 1: Exploring the background of person-centred care across the spectrum of related cardiometabolic diseases

09:00 - 09:15
(CEST)

The Prologue: welcome and introductions

Alice Cheng, Mikael Rydén
09:15 - 09:35
(CEST)

Chapter 1: Person-centred care - the evolving landscape and new horizons in obesity management

Carel le Roux
09:35 - 09:55
(CEST)

Chapter 2: Person-centred care - the need for treatment of cardiometabolic diseases

John Buse
09:55 - 10:10
(CEST)

Chapter 3: Focus on PAD - synergistic strategies across ASCVD

Subodh Verma
10:10 - 10:25
(CEST)

Chapter 4: Person-centred care - heart failure for people with cardiometabolic diseases

Michele Senni
10:25 - 10:40
(CEST)

Chapter 5: Summarising the evidence for person-centred care across cardiometabolic diseases

Alice Cheng, Mikael Rydén, Carel le Roux, John Buse, Subodh Verma, Michele Senni
10:55 - 12:05
(CEST)

Part 2: Focusing in on an expanding spectrum of cardiometabolic diseases and patient phenotypes

10:55 - 11:00
(CEST)

Checking the contents page: welcome back

Alice Cheng, Mikael Rydén
11:00 - 11:15
(CEST)

Chapter 6: Focus on kidneys - synergistic strategies across cardiometabolic diseases

Christoph Wanner
11:15 - 11:35
(CEST)

Chapter 7: Focus on MASH - integrating emerging data into clinical pathways

Laurent Castera
11:35 - 11:50
(CEST)

Chapter 8: Focus on childhood - charting new paths in obesity management

Antje Körner
11:50 - 12:05
(CEST)

Chapter 9: Summarising the focus and translating it into clinical practice

Alice Cheng, Mikael Rydén, Christoph Wanner, Laurent Castera, Antje Körner
12:45 - 14:10
(CEST)

Part 3: Semaglutide and the path to holistic cardiometabolic disease care

12:45 - 12:50
(CEST)

Checking the contents page: welcome back

Alice Cheng, Mikael Rydén
12:50 - 13:15
(CEST)

Chapter 10: The prequel to semaglutide and the evidence that started the journey

Anna Secher
13:15 - 13:40
(CEST)

Chapter 11: The science of the cardiometabolic care - clinical evidence and perspectives

Arya M. Sharma
13:40 - 13:55
(CEST)

Chapter 12: The voice of the patient - hearing their call to action for personalised care

13:55 - 14:10
(CEST)

Chapter 13: Summarising the journey and exploring the
co-authors’ views

Alice Cheng, Mikael Rydén, Anna Secher, Arya M. Sharma
14:25 - 15:50
(CEST)

Part 4: The future chapters - advancing the management of cardiometabolic diseases

14:25 - 14:30
(CEST)

Checking the contents page: welcome back

Alice Cheng, Mikael Rydén
14:30 - 14:45
(CEST)

Chapter 14: Advancements in nutrient-stimulated hormone therapies: the evolution of amylin

Matthias Blüher
14:45 - 15:00
(CEST)

Chapter 15: Advancements to clinical excellence in obesity through the potential of complementary biologies

W. Timothy Garvey
15:00 - 15:15
(CEST)

Chapter 16: Advancements across the metabolic disease continuum - expanding the evidence

Melanie Davies
15:15 - 15:30
(CEST)

Chapter 17: Advancements in the treatment toolbox - integrating amycretin

Ania Jastreboff
15:30 - 15:50
(CEST)

Chapter 18: Summarising the advancements and looking to a future of clinical excellence

Alice Cheng
16:05 - 17:00
(CEST)

Part 5: Innovating our heritage - once-weekly basal insulin therapy

16:05 - 16:10
(CEST)

Checking the contents page: welcome back

Alice Cheng, Mikael Rydén
16:10 - 16:30
(CEST)

Chapter 19: Innovation in basal insulins - individualised treatment in focus

Athena Philis-Tsimikas, Harald Sourij
16:30 - 16:45
(CEST)

Chapter 20: Innovation in combination insulin therapy - benefits beyond glycaemic control

Linong Ji​​
16:45 - 16:55
(CEST)

Chapter 21: Summarising the innovation for people in need of insulin

Alice Cheng, Mikael Rydén, Athena Philis-Tsimikas, Harald Sourij, Linong Ji​​
16:55 - 17:00
(CEST)

The Epilogue: summary and close

Alice Cheng, Mikael Rydén
Keywords
Diabetes
Obesity
Cardiovascular Disease
Chronic Kidney Disease
NASH
Congress industry session